Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioLife Solutions (BLFS)

BioLife Solutions Q1 revenue rises 30% to $23.9 million; 2025 guidance affirmed

Positive Impact 3 of 5 earnings Written later

BioLife Solutions reported unaudited first-quarter 2025 results, with total revenue of $23.9 million, up 30% from $18.4 million a year earlier. The GAAP net loss from continuing operations narrowed to $0.4 million from $3.2 million, and the company affirmed its 2025 revenue guidance of $95.5 million to $99.0 million.

Key points

  • Q1 2025 total revenue was $23.9 million, up $5.5 million or 30% year over year; Cell Processing revenue rose 33% to $21.6 million.
  • GAAP net loss from continuing operations was $0.4 million, or $0.01 per share, versus $3.2 million, or $0.07 per share, in Q1 2024.
  • Adjusted EBITDA was $5.7 million, or 24% of revenue, compared with $2.6 million, or 14%, a year earlier.
  • The company affirmed 2025 revenue guidance of $95.5 million to $99.0 million, and cash, cash equivalents and marketable securities were $107.6 million as of March 31, 2025.

The filing

CompanyBioLife Solutions (BLFS)
Form8-K, current report
Filed with the SECMay 8, 2025, 4:10 PM ET
Accession number0001628280-25-023798

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:07 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.